J A McDowell

Summary

Affiliation: Glaxo Wellcome
Country: USA

Publications

  1. ncbi Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study
    J A McDowell
    Glaxo Wellcome, Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 43:2855-61. 1999
  2. ncbi Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults
    J A McDowell
    Glaxo Wellcome, Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:1686-90. 2000
  3. ncbi Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults
    J A McDowell
    Worldwide Clinical Pharmacology, Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:2061-7. 2000

Collaborators

Detail Information

Publications3

  1. ncbi Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study
    J A McDowell
    Glaxo Wellcome, Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 43:2855-61. 1999
    ..Two major metabolites, the 5'-carboxylate and the 5'-glucuronide, were identified in urine and, combined, accounted for 66% of the dose. Abacavir showed significant penetration into CSF...
  2. ncbi Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults
    J A McDowell
    Glaxo Wellcome, Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:1686-90. 2000
    ..In conclusion, while a single 600-mg dose of abacavir does not alter blood ethanol concentration, ethanol does increase plasma abacavir concentrations...
  3. ncbi Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults
    J A McDowell
    Worldwide Clinical Pharmacology, Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:2061-7. 2000
    ..05). The incidence of nausea was significantly associated with total daily AUC(tau) and C(max). In conclusion, abacavir has predictable pharmacokinetic characteristics following the administration of multiple doses...